Antiviral Drugs Segmentation
Route of Administration (Oral, Injectable, Topical)
The oral segment is projected to dominate with the largest share of 57.5% in the antiviral drugs market by the end of 2037. The segment’s growth is highly driven by cost-effectiveness, patient compliance, and convenience. Oral antivirals such as hepatitis C DAAs and HIV protease inhibitors effectively constitute treatment protocols, owing to their established profiles, along with high bioavailability. As per the 2024 U.S. FDA report, more than 72% of the latest accepted antivirals are oral formulations, which positively reflects industry prioritization of remote dosage services, thereby suitable for the segment’s upliftment.
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
The hospital pharmacies segment is expected to hold the second-largest share of 39.2% in the antiviral drugs market by the end of the forecast timeline. This particular segment serves as the primary channel for catering to complicated therapies and acute treatments. In addition, the growth originates from inpatient demand for IV antivirals as well as specialty medications, including HCV/HIV regimens that require clinical observation. As per the 2024 CDC report, an estimated 66% of pandemic stockpile antivirals are supplied through hospital facilities that ensure fast deployment during outbreaks, thus denoting an optimistic outlook for the segment.
Our in-depth analysis of the global market includes the following segments:
Route of Administration |
|
Distribution Channel |
|
Drug Class |
|
Indication |
|